Ube has agreed to acquire all of the shares of the CDMO and API manufacturer API Corporation (APIC) from its Japanese compatriot Mitsubishi Chemical. Terms were not disclosed.

APIC offers such CDMO services for small molecule drugs as synthetic route design, pilot manufacturing, investigational medical manufacturing and commercial production based on capabilities in both organic synthesis and biotechnology it has cultivated over many years. It also makes APIs and intermediates.

The US subsidiary of Mitsubishi Chemical (MCC) has entered into a definitive agreement to acquire Gelest from private equity firm New Mountain Capital, which had owned the firm since 2017. The deal should be completed within 2020, subject to regulatory review and approval. Terms were not disclosed.